The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs. Symptoms of ...
Patients with atopic dermatitis (AD) who received ruxolitinib cream experienced a rapid, clinically meaningful, and sustained improvement in their itch. Patients with atopic dermatitis (AD) who ...
Please provide your email address to receive an email when new articles are posted on . Pediatric patients with atopic dermatitis who were treated with dupilumab and topical corticosteroids ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to ...
Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream ...
– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 Results showed that patients with AD treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback